Search
Displaying 131–140 of 729 for “retinal diseases”
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
Career Development Program (CDA)
Objective/Goal: The goal of this Program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of retinal degenerative diseases and to develop innovative strategies to prevent, treat and cure these diseases. This program supports up to five junior-level faculty for five (5) years. $75,000/year
